Big research projects from many countries have shown that the kidney medicine finerenone can help far more people than doctors currently think.
What the Drug Does
The pill protects kidneys, lowers heart‑related problems, and helps people live longer. It works for patients with diabetes, those without diabetes, and some with special kidney disorders.
Study 1: Slowing Kidney Damage
In the FIND‑CKD trial, 1,584 adults with non‑diabetic kidney disease took finerenone along with their regular medicines. Their kidneys got worse more slowly than those who only got standard care. The drug also cut the chance of kidney failure, heart failure, or death by about 23%.
Study 2: Helping Glomerular Disease
Another research group looked at people with glomerular diseases—conditions where the kidney’s filters are damaged by the immune system. Finerenone lowered the risk of kidney failure or disease getting worse by 26% and reduced protein in the urine by 42% after one year.
Study 3: Combining All Data
A third analysis mixed results from the FIND‑CKD trial with two earlier studies of patients with diabetic kidney disease. Together, 14,574 participants were examined. Finerenone cut the risk of kidney failure or disease progression by 24%, reduced hospital stays for heart failure or death by 20%, and lowered overall death risk by 12%.
Why This Matters
Kidney disease affects about 1 in 10 people worldwide—roughly 850 million individuals. It is already a leading cause of illness and death and may become the fifth biggest cause of early death by 2040. Early, effective treatment can keep people out of the hospital and improve their lives.
Safety
The medicine was generally safe. Some users had higher potassium levels, but serious problems or stopping the drug because of this were rare.
Big Picture
Experts say expanding finerenone to more kidney patients could lower kidney failure and heart problems for millions around the world.